Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
Top Cited Papers
Open Access
- 18 March 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 25 (7), 1153-1158
- https://doi.org/10.1038/leu.2011.44
Abstract
Alterations in DNA methylation have been implicated in the pathogenesis of myelodysplastic syndromes (MDS), although the underlying mechanism remains largely unknown. Methylation of CpG dinucleotides is mediated by DNA methyltransferases, including DNMT1, DNMT3A and DNMT3B. DNMT3A mutations have recently been reported in patients with de novo acute myeloid leukemia (AML), providing a rationale for examining the status of DNMT3A in MDS samples. In this study, we report the frequency of DNMT3A mutations in patients with de novo MDS, and their association with secondary AML. We sequenced all coding exons of DNMT3A using DNA from bone marrow and paired normal cells from 150 patients with MDS and identified 13 heterozygous mutations with predicted translational consequences in 12/150 patients (8.0%). Amino acid R882, located in the methyltransferase domain of DNMT3A, was the most common mutation site, accounting for 4/13 mutations. DNMT3A mutations were expressed in the majority of cells in all tested mutant samples regardless of myeloblast counts, suggesting that DNMT3A mutations occur early in the course of MDS. Patients with DNMT3A mutations had worse overall survival compared with patients without DNMT3A mutations (P=0.005) and more rapid progression to AML (P=0.007), suggesting that DNMT3A mutation status may have prognostic value in de novo MDS.This publication has 40 references indexed in Scilit:
- DNMT3AMutations in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2010
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Nature, 2010
- PML-RARα and Dnmt3a1 Cooperate in vivo to Promote Acute Promyelocytic LeukemiaCancer Research, 2010
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid LeukemiaCancer Cell, 2010
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylationBlood, 2009
- Epigenetics in cancerCarcinogenesis: Integrative Cancer Research, 2009
- Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsBlood, 2009
- Mutation in TET2 in Myeloid CancersThe New England Journal of Medicine, 2009
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AMLBlood, 2009
- De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cellsThe Journal of Experimental Medicine, 2007